Lasofoxifene - Wikipedia
Lasofoxifene, sold under the brand name Fablyn, is a nonsteroidal selective estrogen receptor modulator (SERM) which is marketed by Pfizer in Lithuania and Portugal for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy, [1] [2] and the result of an exclusive research collaboration with Ligand Pharmaceuticals ...
Lasofoxifene: Uses, Interactions, Mechanism of Action - DrugBank …
2008年3月19日 · Lasofoxifene is a non-steroidal 3rd generation selective estrogen receptor modulator (SERM) that selectively binds to both ERα and ERβ with high affinity. It is a naphthalene derivative marketed for prevention and treatment of osteoporosis and for the treatment of vaginal atrophy.
Lasofoxifene in Postmenopausal Women with Osteoporosis
2010年2月25日 · Lasofoxifene is a nonsteroidal selective estrogen-receptor modulator that decreases bone resorption, bone loss, and low-density- lipoprotein (LDL) cholesterol in postmenopausal women. 1 We ...
An emerging generation of endocrine therapies in breast cancer: a ...
2023年4月5日 · Lasofoxifene is a next-generation non-steroidal SERM that differs from other SERMs based on its binding affinity, which is similar to 17β-estradiol, and strong preclinical data in ER-mutated ...
Lasofoxifene found to be a promising treatment for therapy …
2021年5月26日 · University of Chicago researchers have found lasofoxifene outperformed fulvestrant, the current gold-standard drug, in reducing or preventing primary breast cancer tumor growth in mice.
Lasofoxifene Monotherapy Induces Durable Complete Remission …
2023年11月2日 · Lasofoxifene is a nonsteroidal ER ligand that demonstrates tissue selective activity and was originally studied in osteoporosis and vulvar-vaginal atrophy. 13 In vitro and in vivo breast cancer animal models demonstrated significant reduction in tumor cell proliferation in both wild-type and breast cancer cells expressing ESR1 mutations. 12,14 ...
Lasofoxifene as a potential treatment for therapy-resistant ER …
2021年5月12日 · Lasofoxifene is a selective estrogen receptor modulator with benefits on bone health and breast cancer prevention potential. This study investigated the anti-tumor activity of lasofoxifene in breast cancer xenografts expressing Y537S and D538G ERα mutants.
Lasofoxifene: Evidence of its therapeutic value in osteoporosis
2010年6月15日 · Lasofoxifene is a new generation selective estrogen receptor modulator (SERM) that has completed the phase III development program for the prevention and treatment of osteoporosis in postmenopausal women.
Lasofoxifene Combination Therapy Shows Promise for Treatment …
2023年5月15日 · In a phase 2 clinical trial, researchers gave a combination of lasofoxifene and abemaciclib to patients with metastatic breast cancer whose disease had progressed after prior treatment. Patients had a good response rate, with median …
Lasofoxifene for the prevention and treatment of …
2009年11月2日 · Lasofoxifene is a selective estrogen receptor modulator (estrogen agonist/antagonist) that has completed phase III trials to evaluate safety and efficacy for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy in postmenopausal women.